336 related articles for article (PubMed ID: 11801587)
1. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
Cagnoni PJ
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():81-6. PubMed ID: 11801587
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
Cagnoni PJ; Walsh TJ; Prendergast MM; Bodensteiner D; Hiemenz S; Greenberg RN; Arndt CA; Schuster M; Seibel N; Yeldandi V; Tong KB
J Clin Oncol; 2000 Jun; 18(12):2476-83. PubMed ID: 10856108
[TBL] [Abstract][Full Text] [Related]
3. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
5. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
6. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study.
Slain D; Miller K; Khakoo R; Fisher M; Wierman T; Jozefczyk K
Clin Ther; 2002 Oct; 24(10):1636-42. PubMed ID: 12462292
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.
Wingard JR; Leather HL; Wood CA; Gerth WC; Lupinacci RJ; Berger ML; Mansley EC
Am J Health Syst Pharm; 2007 Mar; 64(6):637-43. PubMed ID: 17353573
[TBL] [Abstract][Full Text] [Related]
8. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
9. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
10. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia.
Fleming RV; Kantarjian HM; Husni R; Rolston K; Lim J; Raad I; Pierce S; Cortes J; Estey E
Leuk Lymphoma; 2001 Feb; 40(5-6):511-20. PubMed ID: 11426524
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature.
Martino R
Curr Med Res Opin; 2004 Apr; 20(4):485-504. PubMed ID: 15119986
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
13. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.
Wingard JR; White MH; Anaissie E; Raffalli J; Goodman J; Arrieta A;
Clin Infect Dis; 2000 Nov; 31(5):1155-63. PubMed ID: 11073745
[TBL] [Abstract][Full Text] [Related]
15. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.
Collins CD; Stuntebeck ER; DePestel DD; Stevenson JG
Clin Drug Investig; 2007; 27(4):233-41. PubMed ID: 17358095
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
19. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.
Sundar S; Goyal AK; More DK; Singh MK; Murray HW
Ann Trop Med Parasitol; 1998 Oct; 92(7):755-64. PubMed ID: 9924533
[TBL] [Abstract][Full Text] [Related]
20. An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections.
Myint H; Kyi AA; Winn RM
J Antimicrob Chemother; 1998 Mar; 41(3):424-6. PubMed ID: 9578177
[No Abstract] [Full Text] [Related]
[Next] [New Search]